Open AccessDOI
Review: Treatment of Helicobacter pylori infection
Aya Ahmed,Gehan F. Balata,Hany M Elsadek,Ahmed Amin +3 more
- Vol. 29, Iss: 2, pp 11-23
TLDR
High-dose dual therapy consisting of amoxicillin and a PPI has been proposed as an effective and safe first-line or rescue therapy due to the bacterial resistance to antibiotics that can limit the applicability of such regimens.Abstract:
Helicobacter pylori (H. pylori) is strongly associated with a wide spectrum of gastrointestinal diseases, such as duodenal or gastric ulcers and gastric cancer. Currently, the main treatment of H.pylori infection involves the use of a combination of antimicrobial agents such as amoxicillin, metronidazole and clarithromycin and proton pump inhibitors (PPIs). In many guidelines, triple therapy consisting of two antibiotics (amoxicillin/metronidazole and clarithromycin) and a PPI is used as the first treatment line. Unfortunately, the increased resistance of H. pylori to clarithromycin and metronidazole adversely affect the effectiveness of triple therapy and reduces the eradication rates to an unacceptable levels. Several regimens has been proposed to replace standard triple therapy such as bismuth-containing quadruple therapy, sequential therapy, concomitant therapy, hybrid therapy and levofloxacin based therapy. Many regimens are used as rescue therapy based on what was previously used in the treatment such as bismuth quadruple therapy, rifabutin triple therapy and levofloxacin based therapies. However, due to the bacterial resistance to antibiotics that can limit the applicability of such regimens and because the resistance to amoxicillin is very low, high-dose dual therapy consisting of amoxicillin and a PPI has been proposed as an effective and safe first-line or rescue therapy.read more
Citations
More filters
Journal ArticleDOI
Review: Treatment of Helicobacter pylori Infection 2019
TL;DR: Several studies showed that the diversity of gut microbiota was significantly altered shortly after H pylori eradication, however, the diversity was restored to pre‐treatment state after 2 months in patients treated with triple therapy.
Journal ArticleDOI
Transformation of Helicobacter pylori into Coccoid Forms as a Challenge for Research Determining Activity of Antimicrobial Substances.
Paweł Krzyżek,Rossella Grande +1 more
TL;DR: The current review aimed at collecting information about the activity of antibacterial substances against H. pylori in the context of the morphological variability of this bacterium in terms of the type of substances used, applied research techniques, and interpretation of results.
Journal ArticleDOI
Helicobacter pylori first‐line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp‐EuReg)
Olga P Nyssen,Ángeles Pérez-Aisa,Bojan Tepes,Luis Rodrigo-Sáez,Pilar Mata Romero,Alfredo J. Lucendo,Manuel Castro-Fernandez,Perminder Phull,Jesus Barrio,Luis Bujanda,Juan Ortuño,Miguel Areia,Natasa Brglez Jurecic,José María Huguet,Noelia Alcaide,Irina Voynovan,José María Botargues Bote,Ines Modolell,Jorge Pérez Lasala,Inés Ariño,Laimas Virginijus Jonaitis,Manuel Domínguez-Cajal,György M. Buzás,Frode Lerang,Monica Perona,Dmitry S. Bordin,Toni Axon,Antonio Gasbarrini,Ricardo Marcos Pinto,Yaron Niv,Limas Kupčinskas,Ante Tonkic,Marcis Leja,Theodore Rokkas,Lyudmila Boyanova,Oleg Shvets,Marino Venerito,Peter Bytzer,Adrian Goldis,Ilkay Simsek,Vincent Lamy,Krzysztof Przytulski,Lumír Kunovský,Lisette G Capelle,Tomica Milosavljevic,Maria Caldas,Ana Garre,Francis Mégraud,Colm O'Morain,Javier P. Gisbert +49 more
TL;DR: Experience in Helicobacter pylori eradication treatment of patients allergic to penicillin is very scarce, so the use of a quadruple therapy with PPI, bismuth, tetracycline, and M has been recommended.
Journal ArticleDOI
In Vitro Activity of Sertraline, an Antidepressant, Against Antibiotic-Susceptible and Antibiotic-Resistant Helicobacter pylori Strains.
Paweł Krzyżek,Roman Franiczek,Barbara Krzyżanowska,Łukasz Łaczmański,Paweł Migdał,Grażyna Gościniak +5 more
TL;DR: Results indicate that sertraline, an antidepressant substance, may be a promising anti-H.
Journal ArticleDOI
The Effect of Probiotics Supplementation on Gut Microbiota After Helicobacter pylori Eradication: A Multicenter Randomized Controlled Trial
Bo Tang,Li Tang,Cheng Huang,Chuan Tian,Ling Chen,Zhijun He,Guodong Yang,Luo Zuo,Guoce Zhao,En Liu,Sumin Wang,Hui Lin,Jialin He,Shi-Ming Yang +13 more
TL;DR: Wang et al. as mentioned in this paper investigated the impact of probiotics on eradication rate and gut microbiota during eradication therapy, and found that probiotics supplementation might help to construct a beneficial profile of gut microbiota after eradication.
References
More filters
Journal ArticleDOI
Helicobacter pylori: epidemiology and routes of transmission.
TL;DR: Overall, inadequate sanitation practices, low social class, and crowded or high-density living conditions seem to be related to a higher prevalence of H. pylori infection, which suggests that poor hygiene and crowded conditions may facilitate transmission of infection among family members and is consistent with data on intrafamilial and institutional clustering of the bacterium.
Journal ArticleDOI
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection
TL;DR: Most patients will be better served by first-line treatment with bismuth quadruple therapy or concomitant therapy consisting of a PPI, clarithromycin, amoxicillin, and metronidazole.
Journal ArticleDOI
Helicobacter pylori treatment in the era of increasing antibiotic resistance
TL;DR: The most commonly recommended triple Helicobacter pylori regimen (proton pump inhibitor (PPI), amoxicillin and clarithromycin) now provides unacceptably low treatment success as discussed by the authors.
Journal ArticleDOI
Helicobacter pylori Infection
TL;DR: A 29-year-old man presents with intermittent epigastric discomfort, without weight loss or evidence of gastrointestinal bleeding, and receives a 10-day course of omeprazole, amoxicillin, and clarithromycin, and he returns with the same symptoms six weeks later.
Journal ArticleDOI
Nano-Strategies to Fight Multidrug Resistant Bacteria-"A Battle of the Titans".
Pedro V. Baptista,Matthew P. McCusker,Andreia Carvalho,Daniela Alves Ferreira,Niamh M. Mohan,Marta Martins,Alexandra R. Fernandes +6 more
TL;DR: The use of nanoparticles still presents a challenge to therapy and much more research is needed in order to overcome this, so the current research on nanoparticles and other nanomaterials are summarized.